MannKind Q3 2023 Earnings Report

MannKind EPS Results

• Actual EPS: $0.01
• Consensus EPS: -$0.02
• Beat/Miss: Beat by +$0.03
• One Year Ago EPS: -$0.06

MannKind Revenue Results

• Actual Revenue: $51.20 million
• Expected Revenue: $50.73 million
• Beat/Miss: Beat by +$470.00 thousand
• YoY Revenue Growth: +56.10%

MannKind Announcement Details

• Quarter: Q3 2023
• Date: 11/7/2023
• Time: After Market Closes

MannKind (NASDAQ:MNKD), a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.